Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M110210200 on April 4, 2002

J. Biol. Chem., Vol. 277, Issue 25, 22685-22691, June 21, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/25/22685    most recent
M110210200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ahamed, J.
Right arrow Articles by Ali, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ahamed, J.
Right arrow Articles by Ali, H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Distinct Roles of Receptor Phosphorylation, G Protein Usage, and Mitogen-activated Protein Kinase Activation on Platelet Activating Factor-induced Leukotriene C4 Generation and Chemokine Production*

Jasimuddin Ahamed and Hydar AliDagger

From the Department of Pathology, University of Pennsylvania School of Dental Medicine, Philadelphia, Pennsylvania 19104

Received for publication, October 24, 2001, and in revised form, March 6, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Platelet activating factor (PAF) interacts with cell surface G protein-coupled receptors on leukocytes to induce degranulation, leukotriene C4 (LTC4) generation, and chemokine CCL2 production. Using a basophilic leukemia RBL-2H3 cell line expressing wild-type PAF receptor (PAFR) and a phosphorylation-deficient mutant (mPAFR), we have previously demonstrated that receptor phosphorylation mediates desensitization of PAF-induced degranulation. Here, we sought to determine the role of receptor phosphorylation on PAF-induced LTC4 generation and CCL2 production. We found that PAF caused a significantly enhanced LTC4 generation in cells expressing mPAFR when compared with PAFR cells. In contrast, PAF-induced CCL2 production was greatly reduced in mPAFR cells. Pertussis toxin and U0126, which inhibit Gi and p44/42 mitogen-activated protein kinase (ERK) activation, respectively, caused very little inhibition of PAF-induced CCL2 production (~20% inhibition). In contrast, these inhibitors almost completely blocked both PAF-induced ERK phosphorylation and LTC4 generation in PAFR cells. However, in mPAFR cells pertussis toxin only partially inhibited PAF-induced ERK phosphorylation. A Ca2+/calmodulin inhibitor had no effect on PAF-induced ERK phosphorylation in PAFR cells but completely blocked the response in mPAFR cells. These data demonstrate that receptor phosphorylation, which serves to desensitize PAF-induced LTC4 generation, is required for chemokine CCL2 production. They also indicate a previously unrecognized selectivity in G protein usage and ERK activation for PAF-induced responses. Whereas PAF-induced CCL2 production is, in large part, mediated independently of Gi activation or ERK phosphorylation, LTC4 generation requires ERK phosphorylation, which is mediated by different G proteins depending on the phosphorylation status of the receptor.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3 phosphocholine, PAF)1 is an important mediator of inflammation that is released from mast cells, platelets, neutrophils, monocytes, and macrophages (1, 2). PAF activates cell surface G protein-coupled receptors (GPCRs) to induce divergent biological functions (3). PAF is a potent leukocyte chemoattractant (4) that also induces degranulation (5, 6), leukotriene C4 (LTC4) generation (7, 8), and chemokine gene expression in a wide variety of cells (9-13). Although much has been learned regarding the signaling pathways involved in PAF-induced chemotaxis and degranulation (4, 6, 14), very little information is available on the mechanism by which PAF stimulates LTC4 generation and chemokine production.

Receptor phosphorylation by G protein-coupled receptor kinase (GRK) and the subsequent recruitment of beta -arrestin are essential for uncoupling the receptor from G proteins (15). Thus, phosphorylation-deficient mutants of chemoattractant receptors expressed in basophilic leukemia RBL-2H3 cells respond to the ligand for enhanced G protein activation, a more sustained Ca2+ mobilization, and a greater extent of degranulation when compared with cells expressing wild-type receptors (14, 16, 17). Receptor phosphorylation and beta -arrestin recruitment have recently been shown to mediate MAP kinase activation for many GPCRs (18-21). However, the chemoattractants formylpeptide and the complement component C3a stimulate ERK phosphorylation via pathways that do not require receptor phosphorylation or beta -arrestin recruitment (17, 22). We have recently shown that C3a receptor phosphorylation by the G protein-coupled receptor kinase provides a stimulatory signal that synergizes with ERK activation to induce chemokine CCL2 (also known as monocytes chemoattractant protein-1 or MCP-1) production (17).

Unlike the C3a receptor, which couples to Gi, the PAF receptor interacts with the Gi and Gq family of G proteins to induce distinct biological responses (4, 23). In the present study, we sought to determine the roles of receptor phosphorylation, G protein usage, and ERK phosphorylation on PAF-induced LTC4 generation and CCL2 production. For this purpose, RBL-2H3 cells expressing the wild-type PAF receptor (PAFR) and a phosphorylation-deficient mutant of PAFR (mPAFR) were used (14). Here, we demonstrate that receptor phosphorylation, which serves to desensitize PAF-induced LTC4 generation, is required for chemokine CCL2 production. Furthermore, CCL2 production is, in large part, mediated independently of Gi activation or ERK phosphorylation. In contrast, LTC4 generation is dependent on ERK phosphorylation, which is mediated via different mechanisms depending on the phosphorylation status of the receptor.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- PAF, fluphenazine, Ro-31-8220, and U0126 were purchased from Calbiochem. [3H]PAF (1-O-hexadecyl-[acetyl-3H(N)]) (499.5 GBq/mmol) was obtained from PerkinElmer Life Sciences. Rabbit anti-p44/42 MAP kinase and anti-phospho-p44/42 MAP kinase antibodies were obtained from New England Biolabs (Beverly, MA). 12CA5 and anti-mouse IgG-R-phycoerythrin antibodies were obtained from Roche Molecular Biochemicals and Southern Biotechnology Associates (Birmingham, AL), respectively. Pertussis toxin (PTX) and all tissue culture reagents were purchased from Invitrogen. Indo-1 acetoxymethyl and Pluronic F-127 were from Molecular Probes (Eugene, OR). A cPLA2 assay kit was purchased from Cayman Chemicals (Ann Arbor, MI). LTC4 sandwich EIA and ECL Western blotting analysis kits were purchased from Amersham Biosciences. A CCL2 sandwich ELISA kit was purchased from BioSource International (Camarillo, CA). Texas Red-conjugated goat anti-mouse IgG was obtained from Jackson ImmunoResearch Laboratories (West Grove, PA).

Cell Culture, Transfection, Ca2+ Mobilization, and Degranulation-- RBL-2H3 cells stably expressing hemaglutinin-tagged PAFR and mPAFR were used in this study (6, 14). The cells were maintained in Dulbecco's modified Eagle's medium supplemented with 15% fetal bovine serum, glutamine (2 mM), penicillin (100 units/ml), and streptomycin (100 µg/ml) (6, 24). To express equivalent receptors, 7 µg of cDNA encoding PAFR and 25 µg cDNA encoding mPAFR were used for transient transfection by electroporation. For studies with beta -arrestin, 20 µg of total cDNA in the ratio of 1:4 for PAFR/mPAFR and beta arr2-GFP (17) were used. Cells were cultured in complete growth medium, and experiments were performed 16-18 h after transfection. Cell surface receptor expression was determined by incubating cells with 12CA5 or an isotope-matched antibody followed by phycoerythrin-conjugated mouse IgG and analyzed on a FACStarPLUS flow cytometer (BD Biosciences, Mountain View, CA). For Ca2+ mobilization, cells (3 × 106) were loaded with 1 µM Indo-1 acetoxymethyl in the presence of 1 µM Pluronic F127 for 30 min at room temperature. Cells were washed, resuspended in 1.5 ml of HEPES-buffered saline, and intracellular Ca2+ mobilization was determined as described previously (6). For degranulation, cells (5 × 104 cells/well) were cultured overnight in a 96-well tissue culture plate. Cells were washed with HEPES-buffered saline, stimulated with PAF, and the extent of degranulation was determined by measuring the release of beta -hexosaminidase (6, 24).

PAF Binding-- Binding studies were performed to evaluate the number of receptors present in PAFR and mPAFR cells as described by Carlson et al. (25). Briefly, RBL-2H3 cells (2 × 105/well) stably expressing PAFR and mPAFR were plated in 24-well dishes. Cells were washed twice with ice-cold buffer and then resuspended in 0.5 ml of the same buffer containing 10 nM [3H]PAF alone or with 10 µM unlabeled PAF. Cells were then incubated for 4 h at 4 °C. Cells were washed with same buffer three times and lysed with 0.5 ml of 0.1% Triton X-100. Bound radioactivity was determined by scintillation counting of the cell lysates. Bmax values were normalized on the basis of cell number by counting the number of cells in three individual wells.

cPLA2 Enzyme Activity-- RBL-2H3 cells (2 × 106/ml) were stimulated with 100 nM PAF for 2 min at 37 °C. The reaction was stopped by adding 3 volumes of ice-cold buffer. Cell pellets were resuspended in 50 µl of phosphate-buffered saline containing protease inhibitors, homogenized briefly in a microhomogenizer (0.2 ml), and centrifuged at 12,000 × g at 4 °C for 15 min. PLA2 activity of the cell free lysate was determined using a cPLA2 assay kit as described in the manufacturer's protocol (Cayman Chemicals).

Assay of Chemokine CCL2 Production and LTC4 Generation-- RBL-2H3 cells (0.4 × 106/well) expressing PAFR or mPAFR were cultured in complete growth medium overnight. Cells were stimulated with PAF for 6 h (CCL2) and 20 min (LTC4) unless otherwise stated. Supernatants were collected and stored frozen at -80 °C until analysis. CCL2 (17) and LTC4 levels were quantified using sandwich ELISA and EIA kits, respectively, as described in the manufacturer's protocols.

Trafficking of GFP-beta Arrestin by Confocal Microscopy-- Cells coexpressing hemagglutinin-tagged receptors with beta arr2-GFP were plated on 35-mm glass bottom dishes (Mat Tek, Ashland, MA). The cells were stimulated with 100 nM PAF for 1 min at 37 °C. The reaction was stopped by adding 3 volumes of cold phosphate-buffered saline, and the cells were then washed and fixed with 2% paraformaldehyde solution for 30 min at room temperature. To visualize cell surface receptor expression, cells were incubated with the 12CA5 antibody followed by the Texas Red-conjugated secondary antibody (Jackson ImmunoResearch). Cells were observed using a laser-scanning confocal microscope (Olympus FluoView, Olympus, Melville, NY) with a 60× lens. The GFP was excited by using a 488-nm argon/krypton laser, and Texas Red was excited at 515-540- and 570-nm band pass filters, respectively (17).

Phosphorylation of ERK-1/ERK-2-- RBL-2H3 cells expressing PAFR or mPAFR were stimulated with PAF (100 nM) in HEPES buffered saline, and the reaction was stopped at different time periods by the addition of a 3-fold excess ice-cold phosphate-buffered saline containing 1 mM sodium orthovanadate. Cells were mixed with an equal volume of 2× SDS sample buffer and heated to 90 °C for 10 min. Samples were electrophoresed in 10% SDS-polyacrylamide gels and transferred onto a nitrocellulose filter. The filter was treated with 3% nonfat milk in phosphate-buffered saline and incubated with an antibody specific for phosphorylated p44/42 MAP kinase. The reaction was detected by enhanced chemiluminescence. The membrane was stripped and reprobed with an antibody that reacts with unphosphorylated p44/42 MAP kinase (17, 26).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Characterization of PAF-induced LTC4 Generation and Chemokine CCL2 Production in Transfected RBL-2H3 Cells-- We have previously shown that PAF stimulates degranulation in RBL-2H3 cells stably expressing PAFR with an EC50 value of 3 nM (6). In the present study, we stimulated these cells with different concentrations of PAF and determined LTC4 generation and chemokine CCL2 production. As for degranulation, PAF stimulated both LTC4 generation and CCL2 production with an EC50 of ~3 nM (Fig. 1, A and B). However, there were remarkable differences in the time course of these responses. For example, LTC4 generation was essentially complete within 1 min after stimulation (Fig. 1C). In contrast, CCL2 production was not evident until 2 h, reached a peak at ~6 h, and remained elevated for up to 18 h after stimulation (Fig. 1D).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 1.   Dose and time dependence of PAF-induced LTC4 generation and CCL2 production. RBL-2H3 cells stably expressing wild-type PAFR were stimulated with different concentrations of PAF for 20 min or 6 h (A and B) or with a fixed concentration of PAF (100 nM) for the indicated time periods (C and D). LTC4 generation and CCL2 production were quantified by EIA and a sandwich ELISA, respectively. Basal values of 20.3 ± 1.2 (CCL2) and 16.6 ± 0.9 (LTC4) were subtracted from the values shown. The data shown are from one of three similar experiments.

Roles of Receptor Phosphorylation and beta -Arrestin Recruitment on PAF-induced LTC4 Generation and CCL2 Production-- We have previously shown that receptor phosphorylation leads to the desensitization of PAF-induced degranulation in leukocytes (14). To determine the role of receptor phosphorylation on PAF-induced LTC4 generation and CCL2 production, RBL-2H3 cells expressing wild-type PAFR and phosphorylation-deficient mutant mPAFR were used (14). PAF stimulated an equivalent Ca2+ mobilization in PAFR and mPAFR cells (Fig. 2A). PAF-induced LTC4 generation requires Ca2+-dependent activation of cPLA2 (27). Therefore, the ability of PAF to stimulate cPLA2 activity in PAFR and mPAFR cells was determined. As shown in Fig. 2B, PAF caused equivalent cPLA2 activity in PAFR and mPAFR cells. PAF also stimulated the generation of LTC4 in PAFR and mPAFR cells to similar levels (Fig. 2C). The incubation of PAFR cells with PAF for 6 h resulted in maximal CCL2 production (Figs. 1D and 2D). Under this condition, PAF did not cause CCL2 production in mPAFR cells (Fig. 2D) despite the fact that this mutated receptor signals for Ca2+ mobilization, PLA2 activity, and LTC4 generation (Fig. 2, A-C). The possibility that the lack of CCL2 production in mPAFR cells reflects a slower rate of production is unlikely because incubation of these cells with PAF for up to 18 h failed to induce any chemokine (Fig. 2D, inset).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 2.   Effects of receptor phosphorylation on PAF-induced Ca2+ mobilization, cPLA2 activity, LTC4 generation, and CCL2 production in RBL-2H3 cells stably expressing PAFR and mPAFR. A, RBL-2H3 cells stably expressing wild-type PAFR or a phosphorylation-deficient mutant (mPAFR) were loaded with Indo-1 acetoxymethyl and stimulated with PAF (100 nM), and Ca2+ mobilization was determined. B, cells were stimulated with PAF (100 nM) for 2 min, and cPLA2 activity in cell lysate was determined as described in the "Experimental Procedures" section. C, cells were stimulated with PAF (100 nM) for 20 min, and the supernatants were removed and assayed for LTC4 generation by EIA. D, cells were stimulated with PAF (100 nM) for 6 h, and the supernatants were removed and assayed for CCL2 production by ELISA. Open bars, -PAF; filled bars, +PAF. The inset to panel D shows the time course of CCL2 production in response to 100 nM PAF in PAFR and mPAFR cells. The data shown are from one of three similar experiments.

Receptor-ligand binding studies were performed to evaluate the number of receptors present in the cells used in the experiments described above. RBL-2H3 cells expressed 152,300 ± 2,906 (n = 3) PAFRs per cell. In contrast, mPAFR cells expressed 28,630 ± 753 (n = 3) receptors per cell. It is therefore quite possible that the inability of PAF to stimulate CCL2 production in mPAFR cells reflects the expression of lower receptor numbers than PAFR. We were previously unsuccessful in generating stable transfectants in RBL-2H3 cells expressing high levels of mPAFR. For this reason, we optimized a transient transfection procedure to express PAFR and mPAFR at similar levels. Flow cytometric analysis of receptor expression using the 12CA5 antibody is shown in Fig. 3A. Using this system, we tested the effects of PAF on LTC4 generation, degranulation, and CCL2 production. PAF stimulated significantly enhanced LTC4 generation and degranulation in mPAFR cells when compared with PAFR cells (Fig. 3, B and C). In contrast, the ability of PAF to induce CCL2 production in mPAFR cells was ~60% less than that observed in PAFR cells (Fig. 3D). These data suggest that receptor phosphorylation, which desensitizes PAF-induced degranulation and LTC4 generation, provides a stimulatory signal for CCL2 production.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of receptor phosphorylation on PAF-induced LTC4 generation, degranulation, and CCL2 production in RBL-2H3 cells transiently expressing PAFR and mPAFR. Transient transfectants were generated in RBL-2H3 cells expressing hemagglutinin-tagged PAFR or mPAFR. Cell surface receptor expression was determined by flow cytometry using the 12CA5 antibody (A). Cells were stimulated with PAF (100 nM) for 20 min, and the supernatants were removed and assayed for LTC4 generation (B) and beta -hexosaminidase release (C). Cells were stimulated with PAF (100 nM) for 6 h; the supernatants were removed and assayed for CCL2 production by ELISA (D). Con, control; *, p < 0.05; **, <0.01; ***, <0.001 versus the response in PAFR cells.

Ligand-induced receptor phosphorylation is associated with the translocation of beta -arrestin from the cytosol to the plasma membrane (28, 29). To determine whether beta -arrestin recruitment correlates with PAF-induced responses, transient transfectants were generated in RBL-2H3 cells coexpressing PAFR or mPAFR and the beta -arrestin 2/green fluorescent protein conjugate (beta arr2-GFP). As shown in Fig. 4A, PAF caused the translocation of beta arr2-GFP from the cytosol to the plasma membrane in PAFR cells. In contrast, PAF did not induce this response in mPAFR cells (Fig. 4B).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 4.   PAF causes translocation of beta arr2-GFP from the cytoplasm to the plasma membrane in PAFR but not in mPAFR cells. RBL-2H3 cells transiently coexpressing PAFR and beta arr2-GFP (A) or mPAFR and beta arr2-GFP (B) were stimulated with PAF (100 nM) for 1 min, and the translocation of beta arr2-GFP was determined by confocal microscopy. The data shown are representative of three similar experiments.

Roles of G Protein Usage, Phospholipase Cbeta Activation, and ERK Phosphorylation on PAF-induced CCL2 Production and LTC4 Generation-- PAFR couples to Gi in RBL-2H3 cells to induce chemotaxis (4). PAF also stimulates ERK phosphorylation in Chinese hamster ovary (CHO) cells via a PTX-sensitive G protein (30). In contrast, PAF-induced degranulation requires both Gi and Gq-mediated activation of phospholipase Cbeta , resulting in the activation of protein kinase C (PKC) and the mobilization of Ca2+ (4, 6). We first evaluated the role of signaling through G proteins on PAF-induced CCL2 production and LTC4 generation in PAFR cells. Cells were cultured overnight with or without pertussis toxin (PTX, 100 ng/ml), and its effect on PAF-induced responses was determined. As shown in Fig. 5A, PTX inhibited PAF-induced CCL2 production by 27 ± 3.0%. In contrast, PTX blocked LTC4 generation by 92.6 ± 4.6% (Fig. 5B). To determine the role of phospholipase Cbeta -dependent signaling, we tested the effects of the inhibitors of protein kinase C (Ro-31-8220) and Ca2+/calmodulin (fluphenazine) on PAF-induced responses. Both Ro-31-8220 and fluphenazine almost completely blocked PAF-induced CCL2 production and LTC4 generation (>90% inhibition) (Fig. 5, A and B). To test the role of p44/42 MAP kinase activation on PAF-induced responses, the effect of U0126 was tested. This MAP kinase inhibitor blocked PAF-stimulated CCL2 production by 24 ± 1.3% (Fig. 5A), but it inhibited LTC4 generation by 95 ± 1.5% in PAFR cells (Fig. 5B). The effects of these inhibitors were also tested on PAF-induced LTC4 generation in mPAFR cells. PTX blocked PAF-induced LTC4 generation in mPAFR cells by 51.3 ± 3.7% (Fig 5C). This is in contrast to the situation in PAFR cells where PTX inhibited PAF-induced response by 92.6 ± 4.6% (Fig. 5B). However, as in PAFR cells, Ro-31-8220, fluphenazine, or U0126 almost completely blocked PAF-induced LTC4 generation in mPAFR cells (>90% inhibition) (Fig. 5C).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 5.   Effects of inhibitors on PAF-stimulated CCL2 production and LTC4 generation. RBL-2H3 cells stably expressing PAFR (A and B) or mPAFR (C) were preincubated with PTX (100 ng/ml, overnight), Ro-31-8220 (10 µM, 10 min), fluphenazine (FLU; 30 µM, 30 min) or U0126 (1 µM, 30 min), and PAF (100 nM)-induced CCL2 production in PAFR (A) and LTC4 generation in PAFR (B) and mPAFR (C) cells were determined. CON, control; **, p < 0.01 versus control.

PAF Stimulates ERK Phosphorylation in RBL-2H3 Cells via Different Mechanisms That Depend on the Phosphorylation Status of the Receptor-- As shown above (Fig. 5, B and C), PAF-induced LTC4 generation in PAFR and mPAFR cells appears to be mediated by different G proteins. To test the role of different G protein usage on PAF-induced ERK phosphorylation, the effects of PTX on PAFR and mPAFR responses were determined. As shown in Fig. 6A, PTX caused substantial inhibition of PAF-induced ERK phosphorylation in PAFR cells (91 ± 4.6% inhibition). In contrast, PTX was much less effective in inhibiting this response in mPAFR cells (44 ± 3.0% inhibition) (Fig. 6B). However, Ro-31-8220 caused almost complete inhibition (>90%) of PAF-induced ERK phosphorylation in both cell types (Fig. 6, A and B). Interestingly, fluphenazine had no inhibitory effect on ERK phosphorylation mediated by PAF in PAFR cells (Fig. 6A), but it inhibited the response in mPAFR cells by 95.3 ± 2.3% (Fig 6B). U0126 blocked ERK phosphorylation in response to PAF in both cell types (Fig. 6, A and B).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 6.   PAF stimulates ERK phosphorylation in RBL-2H3 cells via different mechanisms that depend on the phosphorylation status of the receptor. RBL-2H3 cells stably expressing PAFR (A) or mPAFR (B) were incubated with medium (CON, control), PTX (100 ng/ml, overnight), Ro-31-8220 (10 µM, 10 min), fluphenazine (FLU, 30 µM, 30 min), or U0126 (1 µM, 30 min) and stimulated with PAF (100 nM) for 1 min, and ERK phosphorylation was determined by Western blotting using a phospho-ERK-specific antibody. The extent of ERK phosphorylation is expressed as percent of PAF-stimulated responses. ***, p < 0.001 versus the response in PAFR cells.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

PAF plays an important role in inflammatory and cardiovascular diseases (31, 32). PAF stimulates chemotaxis and degranulation in leukocytes (6, 33). It also causes LTC4 generation and chemokine production in a variety of cell types (7, 9-13, 27). We have previously utilized RBL-2H3 cells stably expressing PAFR and a cytoplasmic tail deletion mutant receptor (mPAFR) and demonstrated that receptor phosphorylation plays an important role in the desensitization of PAF-induced degranulation (14). The goal of the present study was to determine the role of receptor phosphorylation on PAF-induced LTC4 generation and chemokine CCL2 production. Here, we demonstrate that receptor phosphorylation desensitizes PAF-induced LTC4 generation but provides a stimulatory signal for chemokine CCL2 production. We also show distinct differences in both G protein usage and ERK phosphorylation on LTC4 generation and CCL2 production.

We recently reported that complement component C3a stimulates CCL2 production via a pathway that requires receptor phosphorylation (17). Furthermore, Schwarz and Murphy (34) showed that Kaposi's sarcoma-associated herpes virus stimulates chemokine gene expression via the activation of a GPCR. However, truncation of the final five amino acids in the cytoplasmic tail of the receptor, which contains one serine and two threonine residues, resulted in a significant decrease in chemokine production. These findings suggest that receptor phosphorylation likely provides a general mechanism for stimulating GPCR-induced chemokine gene expression. The receptor phosphorylation-dependent signal that mediates chemokine production is not known. A substantial and growing body of evidence suggests that the interaction of phosphorylated receptors with the adapter molecule beta -arrestin leads to the formation of a scaffold in the cytoplasm of cells. This complex directly interacts with Src, raf-1, ERK, c-Jun amino terminal kinase 3 (JNK-3), and a small GTP-binding protein, ADP-ribosylation factor 6 (ARF-6), to induce their activation (20, 21, 35). These findings suggest that beta -arrestin could be involved in PAF-induced CCL2 production. The demonstration that PAF caused the recruitment of beta -arrestin in cells expressing PAFR but not mPAFR is consistent with this notion. It is, however, important to note that the ligand-induced phosphorylation of PAFR and the interaction of the phosphorylated receptor with beta -arrestin do not require G protein activation (36). Furthermore, PTX, which had no effect on ligand-induced PAFR phosphorylation (4), caused a substantial inhibition of PAF-induced ERK phosphorylation but had very little effect on CCL2 production. In addition, U0126, which completely blocked PAF-induced ERK phosphorylation, did not cause a substantial inhibition of CCL2 production. These findings suggest that if beta -arrestin mediates PAF-induced CCL2 production, it does so via the activation of a pathway that is mostly independent of G protein activation and ERK phosphorylation.

We have shown in the present study that when PAFR and mPAFR were expressed at similar levels in RBL-2H3 cells, PAF was able to induce CCL2 production in mPAFR cells but at lower level (Fig. 3). Schwarz and Murphy (34) also made a similar observation for a wild-type and a mutant GPCR for a Kaposi's sarcoma-associated herpes virus lacking serine and threonine residues at its carboxyl terminus. These findings suggest that receptor phosphorylation alone does not provide a full signal for chemokine production. This contention is supported by the finding that the inhibition of Galpha q-mediated responses such as Ca2+ mobilization and PKC activation leads to the inhibition of PAF-induced CCL2 production in PAFR cells. We have previously shown that C3a-induced chemokine production requires the interaction of two signals, one receptor phosphorylation-dependent and the other G protein-dependent (17). In contrast to the situation with PAFR, the G protein-dependent signal for the C3a receptor (C3aR) involves Gi-mediated ERK phosphorylation (17). These findings suggest that GPCR-induced chemokine production is mediated via shared (receptor phosphorylation-dependent) and distinct pathways that differ in the G protein usage of the receptor.

The demonstration in the present study that the treatment of cells with U0126 or a Ca2+/calmodulin inhibitor leads to a substantial inhibition of PAF-induced LTC4 generation is consistent with the roles of ERK phosphorylation and Ca2+ mobilization on LTC4 generation (7, 27, 37, 38). Although PAF-induced ERK phosphorylation has been studied in some detail, the mechanism of its activation has not been clearly defined (30, 39-41). The data presented herein indicate that PAF-induced ERK phosphorylation in RBL-2H3 cells is mediated by different mechanisms, depending on the phosphorylation status of the receptor. For example, PAF-induced ERK phosphorylation in PAFR cells requires activation of a PTX-sensitive G protein. In contrast, this response in mPAFR cells involves both PTX-sensitive as well as PTX-insensitive G proteins. We have previously shown that PAF-induced Ca2+ mobilization depends on the activation of Galpha q (6). The demonstration that the Ca2+/calmodulin inhibitor fluphenazine blocked ERK phosphorylation in mPAFR but not PAFR cells raises the intriguing possibility that receptor phosphorylation modulates the G protein-coupling specificity of PAF-induced ERK phosphorylation.

In summary, we have previously shown that receptor phosphorylation mediates the desensitization of PAF-induced degranulation (14). In the present study, we demonstrate that receptor phosphorylation also serves to desensitize PAF-induced LTC4 generation but provides a stimulatory signal for chemokine CCL2 production. The activation of many GPCRs leads to LTC4 generation and chemokine gene expression in a variety of cell types (27, 34, 37, 42-46). Therefore, receptor phosphorylation is likely to have a greater impact on cellular functions than previously recognized.

    ACKNOWLEDGEMENTS

We thank Dr. Bruce Shenker and Ali Zekavat (Fluorescence-activated Cell Sorter Core Facility, University of Pennsylvania School of Dental Medicine) and Christopher S. Adams (Confocal Core Facility, University of Pennsylvania School of Dental Medicine), for assistance with fluorescence-activated cell sorter analysis and confocal microscopy, respectively. We also thank Dr. Marc Caron (Duke University) for providing the cDNA encoding beta -arrestin 2-GFP.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants HL-54166 and HL-63372.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Pathology, University of Pennsylvania School of Dental Medicine, 4010 Locust St. (346 Levy Bldg.), Philadelphia, PA 19104-6002. Tel.: 215-573-1993; Fax: 215-573-2050; E-mail: ali@path.dental.upenn.edu.

Published, JBC Papers in Press, April 4, 2002, DOI 10.1074/jbc.M110210200

    ABBREVIATIONS

The abbreviations used are: PAF, platelet-activating factor; GPCR, G protein-coupled receptor; LTC4, leukotriene C4; MAP, mitogen-activated protein; ERK, extracellular signal-regulated kinase; CCL2, CC chemokine receptor ligand 2 (formerly known as MCP-1); PAFR, PAF receptor; mPAFR, mutant PAFR; PTX, pertussis toxin; cPLA2, cytosolic phospholipase A2; EIA, enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; beta arr2, beta -arrestin 2; GFP, green fluorescent protein.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Venable, M. E., Zimmerman, G. A., McIntyre, T. M., and Prescott, S. M. (1993) J. Lipid Res. 34, 691-702[Medline] [Order article via Infotrieve]
2. Braquet, P., Touqui, L., Shen, T. Y., and Vargaftig, B. B. (1987) Pharmacol. Rev. 39, 97-145[Medline] [Order article via Infotrieve]
3. Izumi, T., and Shimizu, T. (1995) Biochim. Biophys. Acta 1259, 317-333[Medline] [Order article via Infotrieve]
4. Haribabu, B., Zhelev, D. V., Pridgen, B. C., Richardson, R. M., Ali, H., and Snyderman, R. (1999) J. Biol. Chem. 274, 37087-37092[Abstract/Free Full Text]
5. Verghese, M. W., Charles, L., Jakoi, L., Dillon, S. B., and Snyderman, R. (1987) J. Immunol. 138, 4374-4380[Abstract]
6. Ali, H., Richardson, R. M., Tomhave, E. D., DuBose, R. A., Haribabu, B., and Snyderman, R. (1994) J. Biol. Chem. 269, 24557-24563[Abstract/Free Full Text]
7. Syrbu, S. I., Waterman, W. H., Molski, T. F., Nagarkatti, D., Hajjar, J. J., and Sha'afi, R. I. (1999) J. Immunol. 162, 2334-2340[Abstract/Free Full Text]
8. Myou, S., Sano, H., Fujimura, M., Zhu, X., Kurashima, K., Kita, T., Nakao, S., Nonomura, A., Shioya, T., Kim, K. P., Munoz, N. M., Cho, W., and Leff, A. R. (2001) Nat. Immunol. 2, 145-149[CrossRef][Medline] [Order article via Infotrieve]
9. Kravchenko, V. V., Pan, Z., Han, J., Herbert, J. M., Ulevitch, R. J., and Ye, R. D. (1995) J. Biol. Chem. 270, 14928-14934[Abstract/Free Full Text]
10. Maruoka, S., Hashimoto, S., Gon, Y., Takeshita, I., and Horie, T. (2000) Am. J. Respir. Crit. Care Med. 161, 922-929[Abstract/Free Full Text]
11. Roth, M., Nauck, M., Yousefi, S., Tamm, M., Blaser, K., Perruchoud, A. P., and Simon, H. U. (1996) J. Exp. Med. 184, 191-201[Abstract/Free Full Text]
12. Nasu, K., Narahara, H., Matsui, N., Kawano, Y., Tanaka, Y., and Miyakawa, I. (1999) Mol. Hum. Reprod. 5, 548-553[Abstract/Free Full Text]
13. Jocks, T., Freudenberg, J., Zahner, G., and Stahl, R. A. (1998) Nephrol. Dial. Transplant. 13, 37-43[Abstract/Free Full Text]
14. Richardson, R. M., Haribabu, B., Ali, H., and Snyderman, R. (1996) J. Biol. Chem. 271, 28717-28724[Abstract/Free Full Text]
15. Lefkowitz, R. J., Inglese, J., Koch, W. J., Pitcher, J., Attramadal, H., and Caron, M. G. (1992) Cold Spring Harbor Symp. Quant. Biol. 57, 127-133[Abstract/Free Full Text]
16. Richardson, R. M., DuBose, R. A., Ali, H., Tomhave, E. D., Haribabu, B., and Snyderman, R. (1995) Biochemistry 34, 14193-14201[CrossRef][Medline] [Order article via Infotrieve]
17. Ahamed, J., Haribabu, B., and Ali, H. (2001) J. Immunol. 167, 3559-3563[Abstract/Free Full Text]
18. Luttrell, L. M., Roudabush, F. L., Choy, E. W., Miller, W. E., Field, M. E., Pierce, K. L., and Lefkowitz, R. J. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 2449-2454[Abstract/Free Full Text]
19. Daaka, Y., Luttrell, L. M., Ahn, S., Della Rocca, G. J., Ferguson, S. S., Caron, M. G., and Lefkowitz, R. J. (1998) J. Biol. Chem. 273, 685-688[Abstract/Free Full Text]
20. Luttrell, L. M., Ferguson, S. S., Daaka, Y., Miller, W. E., Maudsley, S., Della Rocca, G. J., Lin, F., Kawakatsu, H., Owada, K., Luttrell, D. K., Caron, M. G., and Lefkowitz, R. J. (1999) Science 283, 655-661[Abstract/Free Full Text]
21. Miller, W. E., and Lefkowitz, R. J. (2001) Curr. Opin. Cell Biol. 13, 139-145[CrossRef][Medline] [Order article via Infotrieve]
22. Gilbert, T. L., Bennett, T. A., Maestas, D. C., Cimino, D. F., and Prossnitz, E. R. (2001) Biochemistry 40, 3467-3475[CrossRef][Medline] [Order article via Infotrieve]
23. Ali, H., Richardson, R. M., Haribabu, B., and Snyderman, R. (1999) J. Biol. Chem. 274, 6027-6030[Free Full Text]
24. Ali, H., Richardson, R. M., Tomhave, E. D., Didsbury, J. R., and Snyderman, R. (1993) J. Biol. Chem. 268, 24247-24254[Abstract/Free Full Text]
25. Carlson, S. A., Chatterjee, T. K., and Fisher, R. A. (1996) J. Biol. Chem. 271, 23146-23153[Abstract/Free Full Text]
26. Ali, H., Ahamed, J., Hernandez-Munain, C., Baron, J. L., Krangel, M. S., and Patel, D. D. (2000) J. Immunol. 165, 7215-7223[Abstract/Free Full Text]
27. Hirabayashi, T., Kume, K., Hirose, K., Yokomizo, T., Iino, M., Itoh, H., and Shimizu, T. (1999) J. Biol. Chem. 274, 5163-5169[Abstract/Free Full Text]
28. Barak, L. S., Ferguson, S. S., Zhang, J., and Caron, M. G. (1997) J. Biol. Chem. 272, 27497-27500[Abstract/Free Full Text]
29. Cao, W., Luttrell, L. M., Medvedev, A. V., Pierce, K. L., Daniel, K. W., Dixon, T. M., Lefkowitz, R. J., and Collins, S. (2000) J. Biol. Chem. 275, 38131-38134[Abstract/Free Full Text]
30. van Biesen, T., Hawes, B. E., Raymond, J. R., Luttrell, L. M., Koch, W. J., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 1266-1269[Abstract/Free Full Text]
31. Ishii, S., and Shimizu, T. (2000) Prog. Lipid Res. 39, 41-82[CrossRef][Medline] [Order article via Infotrieve]
32. Montrucchio, G., Alloatti, G., and Camussi, G. (2000) Physiol. Rev. 80, 1669-1699[Abstract/Free Full Text]
33. Haribabu, B., and Snyderman, R. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9398-9402[Abstract/Free Full Text]
34. Schwarz, M., and Murphy, P. M. (2001) J. Immunol. 167, 505-513[Abstract/Free Full Text]
35. Claing, A., Chen, W., Miller, W. E., Vitale, N., Moss, J., Premont, R. T., and Lefkowitz, R. J. (2001) J. Biol. Chem. 276, 42509-42513[Abstract/Free Full Text]
36. Chen, Z., Dupre, D. J., Le, Gouill, C., Rola-Pleszczynski, M., and Stankova, J. (2002) J. Biol. Chem. 277, 7356-7362[Abstract/Free Full Text]
37. Miura, K., Schroeder, J. T., Hubbard, W. C., and MacGlashan, D. W., Jr. (1999) J. Immunol. 162, 4198-4206[Abstract/Free Full Text]
38. Qiu, Z. H., Gijon, M. A., de Carvalho, M. S., Spencer, D. M., and Leslie, C. C. (1998) J. Biol. Chem. 273, 8203-8211[Abstract/Free Full Text]
39. Honda, Z., Takano, T., Gotoh, Y., Nishida, E., Ito, K., and Shimizu, T. (1994) J. Biol. Chem. 269, 2307-2315[Abstract/Free Full Text]
40. Ferby, I. M., Waga, I., Sakanaka, C., Kume, K., and Shimizu, T. (1994) J. Biol. Chem. 269, 30485-30488[Abstract/Free Full Text]
41. Ferby, I. M., Waga, I., Hoshino, M., Kume, K., and Shimizu, T. (1996) J. Biol. Chem. 271, 11684-11688[Abstract/Free Full Text]
42. Pan, Z. K. (1998) Biochim. Biophys. Acta 1443, 90-98[Medline] [Order article via Infotrieve]
43. Pan, Z. K., Chen, L. Y., Cochrane, C. G., and Zuraw, B. L. (2000) J. Immunol. 164, 404-411[Abstract/Free Full Text]
44. Huang, S., Chen, L. Y., Zuraw, B. L., Ye, R. D., and Pan, Z. K. (2001) J. Biol. Chem. 276, 40977-40981[Abstract/Free Full Text]
45. Briscoe, C., Moniakis, J., Kim, J. Y., Brown, J. M., Hereld, D., Devreotes, P. N., and Firtel, R. A. (2001) Dev. Biol. 233, 225-236[CrossRef][Medline] [Order article via Infotrieve]
46. Leslie, C. C. (1997) J. Biol. Chem. 272, 16709-16712[Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
FASEB J.Home page
W.-C. Chang, C. Nelson, and A. B. Parekh
Ca2+ influx through CRAC channels activates cytosolic phospholipase A2, leukotriene C4 secretion, and expression of c-fos through ERK-dependent and -independent pathways in mast cells
FASEB J, November 1, 2006; 20(13): 2381 - 2383.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. L. Brown, V. R. Jala, S. K. Raghuwanshi, M. W. Nasser, B. Haribabu, and R. M. Richardson
Activation and regulation of platelet-activating factor receptor: role of gi and gq in receptor-mediated chemotactic, cytotoxic, and cross-regulatory signals.
J. Immunol., September 1, 2006; 177(5): 3242 - 3249.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
B. O. Ibe, A. M. Portugal, S. Chaturvedi, and J. U. Raj
Oxygen-dependent PAF receptor binding and intracellular signaling in ovine fetal pulmonary vascular smooth muscle
Am J Physiol Lung Cell Mol Physiol, May 1, 2005; 288(5): L879 - L886.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. T. Venkatesha, J. Ahamed, C. Nuesch, A. K. Zaidi, and H. Ali
Platelet-activating Factor-induced Chemokine Gene Expression Requires NF-{kappa}B Activation and Ca2+/Calcineurin Signaling Pathways: INHIBITION BY RECEPTOR PHOSPHORYLATION AND {beta}-ARRESTIN RECRUITMENT
J. Biol. Chem., October 22, 2004; 279(43): 44606 - 44612.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Ahamed, R. T. Venkatesha, E. B. Thangam, and H. Ali
C3a Enhances Nerve Growth Factor-Induced NFAT Activation and Chemokine Production in a Human Mast Cell Line, HMC-1
J. Immunol., June 1, 2004; 172(11): 6961 - 6968.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Skelton, M. Cooper, M. Murphy, and A. Platt
Human Immature Monocyte-Derived Dendritic Cells Express the G Protein-Coupled Receptor GPR105 (KIAA0001, P2Y14) and Increase Intracellular Calcium in Response to its Agonist, Uridine Diphosphoglucose
J. Immunol., August 15, 2003; 171(4): 1941 - 1949.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/25/22685    most recent
M110210200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ahamed, J.
Right arrow Articles by Ali, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ahamed, J.
Right arrow Articles by Ali, H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement